Thalia Therapeutics plc has announced a transformative acquisition of Sanmirna Therapeutics Inc. for its clinical-stage Acute Myeloid Leukaemia RNA therapy, miRisten, for an initial consideration of £3.675 million plus up to £13 million in deferred milestone payments. This acquisition, which propels Thalia into clinical-stage development, is accompanied by an oversubscribed £2.75 million fundraise at 0.6p per share, with directors and vendors subscribing for £1,292,500. The proceeds will fund the completion of the miRisten Phase 1 clinical trial, with top-line data expected in H1 2027, and advance Thalia's cardiovascular assets to FDA IND status, ensuring the work programme is funded through mid-2027.
